Table 3.

Association between patterns of reperfusion therapy and in-hospital MACE.

Therapy patterns	Case/Number∗	Unadjusted HR (95% CI)	P value	Adjusted† HR (95% CI)	P value
No Reperfusion	622/21,778	1.00	–	1.00	–
Fibrinolysis alone	59/2782	0.62 (0.45–0.85)	0.003	0.79 (0.54–1.15)	0.210
Primary PCI
< 12 h	483/28,100	0.65 (0.57–0.74)	<0.001	0.64 (0.54–0.76)	<0.001
12–24 h	72/4635	0.52 (0.39–0.69)	<0.001	0.53 (0.37–0.74)	<0.001
Pharmaco-invasive strategy	19/1745	0.39 (0.23–0.64)	<0.001	0.46 (0.25–0.82)	0.009

^∗The number of in-hospital MACEs was not available for 407 (0.7%) patients who experienced MACEs within 1 day of admission or had missing data regarding the detailed PCI strategies.

^†The adjusted model was clustered for patients within hospitals, and adjusted for age, sex, medical insurance, time from symptom onset to admission, severe clinical conditions at admission (acute heart failure, cardiogenic shock, cardiac arrest), vital signs (heart rate, systolic blood pressure, eGFR), diabetes mellitus, smoking, chronic heart failure, history of disease (coronary heart disease, renal failure, and cerebrovascular disease), transfer status, and medications administered in the first 24 h of arrival (DAPT, β-blockers, and ACEI/ARB). ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; CI: Confidence interval; DAPT: Dual antiplatelet therapy; eGFR: Estimated glomerular filtration rate; HR: Hazard ratio; MACE: Major adverse cardiovascular event; PCI: Percutaneous coronary intervention.